Qichao Xie
- Cancer Research top 10%
- Cancer-related molecular mechanisms research 5
- Cancer, Hypoxia, and Metabolism 2
- MicroRNA in disease regulation 2
-
- RNA modifications and cancer 5
- Sensory Systems top 10%
- Ion Channels and Receptors 2
-
- Cancer-related Molecular Pathways 3
- Lymphatic System and Diseases 2
-
- Lung Cancer Treatments and Mutations 5
- Journals
- Pharmacology (1 paper)Cell Death and Disease (1 paper)Technology in Cancer Research & Treatment (1 paper)
- Partner nations
- ChinaUnited StatesIndia
In The Last Decade
Qichao Xie
24 papers receiving 596 citations
Peers
Comparison fields: 5 of 80
- Cancer Research 266
- Molecular Biology 424
- Sensory Systems 27
- Oncology 121
- Immunology 90
Countries citing papers authored by Qichao Xie
This map shows the geographic impact of Qichao Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qichao Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qichao Xie more than expected).
Fields of papers citing papers by Qichao Xie
This network shows the impact of papers produced by Qichao Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qichao Xie. The network helps show where Qichao Xie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Qichao Xie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 2 | |
| 5 | 2022 | 5 | |
| 6 | 2021 | 20 | |
| 7 | 2021 | 4 | |
| 8 | 2021 | 9 | |
| 9 | 2019 | 26 | |
| 10 | 2017 | 177 | |
| 11 | MDM2 SNP309 variation confers the susceptibility to hepatocellular cancer: a meta-analysis based on 4271 subjects. | 2015 | 4 |
| 12 | 2015 | 63 | |
| 13 | Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study. | 2015 | 11 |
| 14 | 2014 | 37 | |
| 15 | 2014 | 22 | |
| 16 | 2010 | 48 | |
| 17 | 2010 | 25 | |
| 18 | 2009 | 61 | |
| 19 | 2008 | 39 | |
| 20 | 2005 | 11 |
About Qichao Xie
Qichao Xie is a scholar working on Cancer Research, Sensory Systems and Biological Psychiatry, having authored 25 papers that have together received 611 indexed citations. Recurring topics across this work include RNA modifications and cancer (5 papers), Cancer-related molecular mechanisms research (5 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer-related Molecular Pathways (3 papers), Cancer, Hypoxia, and Metabolism (2 papers), Lymphatic System and Diseases (2 papers), MicroRNA in disease regulation (2 papers) and Ion Channels and Receptors (2 papers). The work is most often cited by research in Cancer Research (266 citations), Molecular Biology (424 citations) and Sensory Systems (27 citations). Qichao Xie has collaborated with scholars based in China, United States and India. Frequent co-authors include Yongsheng Li, Jun He, Hailin Xu, Bo Zhu, Yupeng Yang, Zhengtang Chen, Jianfei Gao, Bicheng Zhang, Zhengtang Chen and Duyun Ye. Their work appears in journals such as Pharmacology, Cell Death and Disease, Technology in Cancer Research & Treatment, Frontiers in Immunology and Cell Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.